Back to top

Image: Bigstock

Epizyme, Inc.

Read MoreHide Full Article

Epizyme’s lead candidate, tazemetostat demonstrated clinically meaningful activity, in patients with epithelioid sarcoma, a difficult-to-treat rare cancer. Based on these positive data, the company is confident of its planned new drug application submission for the indication in the first half of 2019. The candidate also showed meaningful activity in patients with follicular lymphoma, both with and without EZH2 activating mutations. Thus, the company is optimistic about the candidate. However, with no approved product in its portfolio, Epizyme is yet to generate revenues. However, the company is making efforts to develop tazemetostat for a number of hematological malignancies and genetically defined solid tumors. Shares of the company have underperformed the industry in past one year.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Epizyme, Inc. (EPZM) - free report >>

Published in